Apolipoprotein E polymorphism in hemodialyzed patients and healthy controls

Biochem Genet. 2009 Oct;47(9-10):688-93. doi: 10.1007/s10528-009-9266-y. Epub 2009 Jun 30.

Abstract

A possible association between end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some but not all studies. We have analyzed the APOE genotypes in 995 hemodialyzed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequency of APOE alleles between cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (P = 0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13-1.67). The strength of the association increased with the time spent on hemodialysis: the odds ratio of all-cause ESRD in patients dialyzed for eight or more years was 1.27 (0.94-1.71), for 1-8 years 1.41 (1.09-1.81), and less than 1 year (nonsurvivors) 1.94 (0.88-4.18). This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Apolipoproteins E / genetics*
  • Case-Control Studies
  • Genotype
  • Health*
  • Humans
  • Kidney Failure, Chronic / genetics*
  • Kidney Failure, Chronic / therapy*
  • Male
  • Polymorphism, Genetic*
  • Renal Dialysis*

Substances

  • Apolipoproteins E